The risk of HBV reactivation by HCV patients undergoing DAA treatment

The risk of HBV reactivation by HCV patients undergoing DAA treatment - Reactivation of HBV during DAA treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025871

Enrollment

200

Registered

2017-01-27

Start date

2015-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients were aged 20 years and older with confirmed chronic HCV infection.

Exclusion criteria

Exclusion criteria: Exclusion criteria included (1) decompensated cirrhosis with Child-Pugh B or C, (2) prior experience of anti-HBV treatment with IFN or nucleos(t)ide analogue, and (3) under treatment with immunosuppressive agents or chemotherapy.

Design outcomes

Primary

Measure	Time frame
The rate of development of HBV reactivation	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results